Exelixis, Inc.(EXEL)
Biotechnology
Oncology Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | WYSZOMIERSKI JACK L Director | Sale | -3,925 | -1.36%284,384 | $50.55 | $198,409 | View SEC filing | |
| 2026-06-03 | Eckhardt Sue Gail Director | Sale | -9,812 | -37.90%16,079 | $50.14 | $491,974 | View SEC filing | |
| 2026-05-28 | Aftab Dana EVP, Research and Development | Sale | -43,451 | -6.81%594,741 | $50.35 | $2,187,758 | View SEC filing | |
| 2026-05-22 | Haley Patrick J. EVP, Commercial | Sale | -32,110 | -8.24%357,638 | $49.81 | $1,599,399 | View SEC filing | |
| 2026-05-19 | Senner Christopher J. EVP and CFO | Sale | -34,901 | -3.54%952,317 | $50.00 | $1,745,050 | View SEC filing | |
| 2026-05-19 | Hefti Brenda SVP and General Counsel | Sale | -6,625 | -5.84%106,762 | $50.21 | $332,641 | View SEC filing | |
| 2026-05-08 | Beckerle Mary C Director | Sale | -7,712 | -30.56%17,524 | $48.45 | $373,646 | View SEC filing | |
| 2026-05-08 | Freire Maria C Director | Sale | -20,634 | -16.99%100,819 | $46.00 | $949,164 | View SEC filing | |
| 2026-05-08 | POSTE GEORGE Director | Sale | -60,000 | -33.55%118,832 | $45.71 | $2,742,600 | View SEC filing | |
| 2026-02-26 | Aftab Dana EVP, Research and Development | Sale | -47,918 | -7.22%616,106 | $44.50 | $2,132,351 | View SEC filing | |
| 2026-02-23 | Aftab Dana EVP, Research and Development | Sale | -29,873 | -4.31%664,024 | $44.35 | $1,324,868 | View SEC filing | |
| 2026-02-20 | WYSZOMIERSKI JACK L Director | Sale | -99,574 | -26.24%279,942 | $44.01 | $4,382,252 | View SEC filing | |
| 2026-02-19 | Smith Julie Director | Sale | -106,539 | -67.32%20,590 | $44.00 | $4,687,346 | View SEC filing | |
| 2026-02-18 | Senner Christopher J. EVP and CFO | Sale | -64,895 | -9.36%976,092 | $43.32 | $2,810,998 | View SEC filing | |
| 2026-02-18 | Haley Patrick J. EVP, Commercial | Sale | -67,814 | -15.08%381,908 | $43.52 | $2,950,941 | View SEC filing | |
| 2026-02-18 | Eckhardt Sue Gail Director | Sale | -3,856 | -18.04%17,524 | $43.79 | $168,854 | View SEC filing | |
| 2026-02-18 | Oliver Bob Director | Sale | -30,250 | -58.89%21,120 | $43.81 | $1,325,339 | View SEC filing | |
| 2026-02-18 | Hefti Brenda SVP and General Counsel | Sale | -18,669 | -16.21%96,512 | $44.01 | $821,623 | View SEC filing | |
| 2025-11-26 | Caligan Partners LP Director, Other | Purchase | +27,532 | +1.80%1,553,262 | $43.12 | $1,187,235 | View SEC filing | |
| 2025-11-24 | Haley Patrick J. EVP, Commercial | Sale | -72,230 | -16.19%374,029 | $42.18 | $3,046,928 | View SEC filing | |
| 2025-11-13 | PAPADOPOULOS STELIOS Director | Sale | -100,000 | -7.76%1,189,228 | $43.55 | $4,355,000 | View SEC filing | |
| 2025-11-13 | Aftab Dana EVP, Research and Development | Sale | -48,383 | -6.78%664,778 | $42.50 | $2,056,278 | View SEC filing | |
| 2025-11-13 | Beckerle Mary C Director | Sale | -24,622 | -53.52%21,380 | $41.93 | $1,032,414 | View SEC filing | |
| 2025-06-04 | Eckhardt Sue Gail Director | Sale | -18,838 | -46.84%21,380 | $42.74 | $805,140 | View SEC filing | |
| 2025-06-04 | WYSZOMIERSKI JACK L Director | Sale | -7,535 | -2.06%358,882 | $43.09 | $324,683 | View SEC filing |
1-25 of 562